Candidate genetic variants included in a genetic risk algorithm may not meet standards of reasonable clinical efficacy in identifying opioid use disorder risk, according to a study published in JAMA ...
The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx ...
The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...
Every year, thousands of people die from overdosing on opioids in the United States. But a new non-opioid pain medication, ...
The Food and Drug Administration (FDA) is hoping a newly approved non-opioid pain medication could help save lives. Dr.
Rutgers Health, in partnership with the New Jersey Department of Labor and Workforce Development (NJDOL), has launched the ...
The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...
Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...
Experts with the Cleveland Clinic say the drug has a lot of potential, especially since it is considered nonaddictive.
Doctors from the Cleveland Clinic talk about how this new non-opioid pain medication could help reduce the issue of opioid ...
US federal officials have approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The US Food and Drug ...
A doctor with NYU says this new pill is not addictive. A mother who lost her son from opioid addiction hopes for the best but wants to see if this new pill will truly be a safe alternative.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback